- Home
- RIGL vs JQC Comparison
RIGL vs JQC Comparison
Compare RIGL & JQC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RIGL | JQC |
|---|---|---|
| Founded | 1996 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 683.2M | 753.9M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | RIGL | JQC |
|---|---|---|
| Price | $33.77 | $5.04 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $43.20 | N/A |
| AVG Volume (30 Days) | 361.6K | ★ 714.6K |
| Earning Date | 03-03-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.13% |
| EPS Growth | ★ 2698.26 | N/A |
| EPS | ★ 6.20 | N/A |
| Revenue | ★ $282,076,000.00 | N/A |
| Revenue This Year | $66.37 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.51 | ★ N/A |
| Revenue Growth | ★ 79.13 | N/A |
| 52 Week Low | $15.50 | $4.82 |
| 52 Week High | $52.24 | $5.65 |
Technical Indicators
Market Signals| Indicator | RIGL | JQC |
|---|---|---|
| Relative Strength Index (RSI) | 34.62 | 42.40 |
| Support Level | $33.05 | $5.03 |
| Resistance Level | $36.65 | $5.17 |
| Average True Range (ATR) | 1.46 | 0.04 |
| MACD | -0.22 | -0.01 |
| Stochastic Oscillator | 7.62 | 10.71 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About JQC Nuveen Credit Strategies Income Fund Shares of Beneficial Interest
Nuveen Credit Strategies Income Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. The fund meets its investment objectives by investing its managed assets in senior secured and second lien loans, and its managed assets across the capital structure of companies (including equity securities) with a primary emphasis on high yield bonds, convertible securities and other forms of income-producing securities.